Antiviral Agents Against COVID-19 Infection

NCT04468087 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

256

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Atazanavir
DRUG: Daclatasvir 60 mg
DRUG: Sofusbuvir + Daclastavir 60 mg
DRUG: Placebo Atazanavir
DRUG: Placebo Daclatasvir 60 mg
DRUG: Placebo Sofusbuvir + Daclatasvir 60 mg

Sponsor

Hospital do Coracao